3,4-methylenedioxymethamphetamine (MDMA) interacts with therapeutic drugs on CYP3A by inhibition of pregnane X receptor (PXR) activation and catalytic enzyme inhibition.

Toxicol Lett March 22, 2011 DOI: 10.1016/j.toxlet.2011.03.007 (opens in new tab)

Study at a glance

AI-extracted from the abstract

Characteristics	Peer reviewed
Topics	MDMA
Key points	Reports that MDMA inhibits CYP3A through both PXR activation inhibition and catalytic enzyme inhibition, indicating a potential for drug-drug interactions.

Abstract

3,4-methylenedioxymethamphetamine (MDMA) interacts with therapeutic drugs on CYP3A by inhibition of pregnane X receptor (PXR) activation and catalytic enzyme inhibition.

The Consequences of 3,4-Methylenedioxymethamphetamine Induced CYP2D6 Inhibition in Humans Journal of Clinical Psychopharmacology September 12, 2008 68 citations
MDMA interactions with pharmaceuticals and drugs of abuse Expert Opinion on Drug Metabolism & Toxicology March 31, 2020 34 citations
Pharmacokinetics and pharmacodynamics of 3,4-methylenedioxymethamphetamine (MDMA): interindividual differences due to polymorphisms and drug–drug interactions Critical Reviews in Toxicology October 3, 2012 51 citations
Impact of Cytochrome P450 2D6 Function on the Chiral Blood Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine (MDMA) and Its Phase I and II Metabolites in Humans. PLoS One June 15, 2016 18 citations
MDMA: interactions with other psychoactive drugs. Pharmacology, biochemistry, and behavior October 2011

Study at a glance

Abstract

Related reading